Reported about 2 months ago
Investors looking for opportunities in the booming GLP-1 pharmaceutical market should consider Jacobs Solutions, a specialty manufacturing company playing a crucial role in building infrastructure for drug production. With strong ties to Eli Lilly, Jacobs is well-positioned to benefit from the anticipated growth in GLP-1 treatments, highlighted by its recent business spin-offs and a competitive edge in unique projects, making it a compelling investment prospect.
Source: YAHOO